Ensign Peak Advisors
PVLA

Ensign Peak Advisors’s Palvella Therapeutics PVLA Stock Holding History

Ensign Peak Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.89M Buy
51,660
+12,437
+32% +$1.51M 0.01% 480
2026
Q1 		$4.89M Buy
+39,223
New +$4.09M 0.01% 534
2021
Q1 		– Sell
-138
Closed -$28K – 1890
2020
Q4 		$28K Hold
138
– – ﹤0.01% 1844
2020
Q3 		$23K Sell
138
-209
-60% -$47.6K ﹤0.01% 1736
2020
Q2 		$86K Hold
347
– – ﹤0.01% 1640
2020
Q1 		$63K Sell
347
-346
-50% -$87.2K ﹤0.01% 1597
2019
Q4 		$201K Buy
+693
New +$192K ﹤0.01% 1616

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Ensign Peak Advisors's PVLA Position: Q2 2026 in Review

Ensign Peak Advisors increased its Palvella Therapeutics (PVLA) stake by 32% in Q2 2026, buying an estimated $1.51M and bringing the position to 51,660 shares worth $7.89M. The position accounts for 0.01% of the portfolio, ranked #480.

Ensign Peak Advisors first reported a position in PVLA in Q4 2019 and has held it in 7 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Ensign Peak Advisors held 51,660 shares of Palvella Therapeutics worth $7.89M as of Q2 2026.
  • Ensign Peak Advisors bought 12,437 Palvella Therapeutics shares in Q2 2026, an estimated $1.51M.
  • Palvella Therapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #480 holding.
  • Ensign Peak Advisors first reported a position in Palvella Therapeutics in Q4 2019 and has held it in 7 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.